Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related THOR
Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III™ U.S. IDE Clinical Trial
Credit Suisse Reiterates Outperform, Raises Price Target On Thoratec On Updated LVAD Estimates
Related LOW
Lowe's Shrugs Off Negative Seeking Alpha Article
Mike Khouw Sees Unusual Options Activity In Lowe's Companies
A Dividend Growth Leaders Portfolio With A 17.5% Dividend Growth Rate (Seeking Alpha)

Analysts at Goldman Sachs downgraded Thoratec (NASDAQ: THOR) from “buy” to “neutral.” The target price for Thoratec has been lowered from $42 to $37. Thoratec's shares closed at $32.60 on Friday.

Analysts at Oppenheimer downgraded Lowe's Companies (NYSE: LOW) from “outperform” to “perform.” The target price for Lowe's is set to $46. Lowe's shares closed at $42.67 on Friday.

Analysts at Keefe Bruyette & Woods downgraded Bank of America (NYSE: BAC) from “outperform” to “perform.” Bank of America's shares closed at $13.43 on Friday.

Jefferies downgraded Bed Bath & Beyond (NASDAQ: BBBY) from “buy” to “hold.” The target price for Bed Bath & Beyond has been lowered from $76 to $71. Bed Bath & Beyond's shares closed at $69.11 on Friday.

Latest Ratings for THOR

DateFirmActionFromTo
Apr 2015OppenheimerMaintainsOutperform
Apr 2015Wunderlich
Feb 2015Canaccord GenuityMaintainsBuy

View More Analyst Ratings for THOR
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (BBBY + BAC)

Around the Web, We're Loving...

Get Benzinga's Newsletters